KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Intangibles (2016 - 2025)

AbbVie (ABBV) has disclosed Intangibles for 9 consecutive years, with $711.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Intangibles changed N/A to $711.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $711.0 million, a N/A change, with the full-year FY2022 number at $67.4 billion, changed N/A from a year prior.
  • Intangibles was $711.0 million for Q3 2025 at AbbVie, down from $57.0 billion in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $79.3 billion in Q2 2021 to a low of $711.0 million in Q3 2025.
  • A 4-year average of $55.3 billion and a median of $63.0 billion in 2022 define the central range for Intangibles.
  • Biggest YoY gain for Intangibles was 14.73% in 2023; the steepest drop was 14.73% in 2023.
  • AbbVie's Intangibles stood at $79.3 billion in 2021, then fell by 15.0% to $67.4 billion in 2022, then fell by 13.1% to $58.6 billion in 2023, then crashed by 98.79% to $711.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Intangibles are $711.0 million (Q3 2025), $57.0 billion (Q2 2025), and $58.6 billion (Q3 2023).